§ 558.305

and 10 to 30 or 250 grams of bacitracin methylene disalicylate.

- (i) Indications for use. For treatment control of gastrointestinal roundworms (Ascaris suum, adults and fourth-stage larvae; Ascarops adults; strongylina, Hyostrongylus rubidus, adults and fourth-stage larvae; Oesophagostomum spp., adults and fourth-stage larvae); kidneyworms (Stephanurus adults and dentatus, fourth-stage lungworms larvae): (Metastrongylus adults): spp. threadworms (Strongyloides ransomi, adults and somatic larvae, and prevention of transmission of infective larvae to piglets, via the colostrum or milk, when fed during gestation); lice (*Haematopinus suis*); and mange mites (Sarcoptes scabiei var. suis). For increased rate of weight gain and improved feed efficiency in growing and finishing swine. For control clostridial enteritis caused by Clostridium perfringens in suckling piglets. For control of swine dysentery associated with Treponema hypdysenteriae on premises with a history of swine dysentery but where signs of disease have not yet occurred, or following an approved treatment of disease condition.
- (ii) Limitations. For use in swine feed only. Feed as the only feed for 7 consecutive days. For weaned growing and finishing swine, feed bacitracin methylene disalicylate Type C medicated feed from weaning to market weight for increased rate of weight gain and improved feed efficiency. For pregnant sows, feed bacitracin methylene disalicylate to sows from 14 ďays before through 21 days after farrowing on premises with a history of clostridial scours. Withdraw ivermectin-containing feeds 5 days before slaughter.

[58 FR 58653, Nov. 3, 1993, as amended at 60 FR 39848, Aug. 4, 1995; 61 FR 32652, June 25, 1996; 62 FR 63271, Nov. 28, 1997; 63 FR 54353, Oct. 9, 1998; 64 FR 13342, Mar. 18, 1999]

§558.305 Laidlomycin.

(a) *Specifications.* Type A medicated articles containing 50 grams

laidlomycin propionate potassium per pound.

- (b) *Approvals.* See No. 046573 in §510.600(c) of this chapter.
- (c) *Tolerances*. See §556.346 of this chapter.
- (d) Special considerations. (1) Laidlomycin liquid Type B feeds may be manufactured from dry laidlomycin Type A articles. The liquid Type B feeds must have a pH of 6.0 to 8.0, dry matter of 62 to 75 percent, and bear appropriate mixing directions as follows:
- (i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.
- (ii) For liquid feeds stored in mechanical, air, or other agitation type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.
- (2) The expiration date for the liquid Type B feed is 21 days after date of manufacture. The expiration date for the dry Type C feed made from the liquid Type B feed is 7 days after date of manufacture.
- (3) Labeling for all Type B feeds (liquid and dry) and Type C feeds containing laidlomycin shall bear the following statements:
- (i) Do not allow horses or other equines access to feeds containing laidlomycin propionate potassium.
- (ii) The safety of laidlomycin propionate potassium in unapproved species has not been established.
- (iii) Not for use in animals intended for breeding.
- (e) *Conditions of use.* It is used in cattle being fed in confinement for slaughter as follows:

Laidlomycin in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
(1) 5		For improved feed efficiency and increased rate of weight gain	Feed continuously in a Type C feed at a rate of 30 to 75 mg/ head/day	046573

Food and Drug Administration, HHS

Laidlomycin in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
(2) 5	Chlortetracycline10 mg/lb body weight.	For improved feed efficiency and increased rate of weight gain; and for treatment of bacterial enteritis caused by <i>Echerichia coli</i> and bacterial pneumonia caused by <i>Pasteurella multocida</i> organisms susceptible to chlortetracycline	Feed continuously at a rate of 30 to 75 mg laidlomycin propionate potassium per head per day for not more than 5 days. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for yeal.	046573
(3) 5	Chlortetracycline 350 mg/head/day.	For improved feed efficiency and increased rate of weight gain; and for control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline	Feed continuously at a rate of 30 to 75 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for yeal.	046573
(4) 5 to 10		For improved feed efficiency	Feed continuously in a Type C feed at a rate of 30 to 150 milligrams/head/day	046573
(5) 5 to 10	Chlortetracycline 10 mg/pound body weight.	For improved feed efficiency; and for treatment of bacterial enteritis caused by <i>E. coli</i> and bacterial pneumonia caused by <i>P. multocida</i> organisms susceptible to chlortetracycline	Feed continuously at a rate of 30 to 150 mg laidlomycin propionate potassium per head per day for not more than 5 days. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for yeal.	046573
(6) 5 to 10	Chlortetracycline 350 mg/head/day.	For improved feed efficiency; and for control of bacterial pneumonia associated with shipping fever complex caused by <i>Pasteurella</i> spp. susceptible to chlortetracycline	Feed continuously at a rate of 30 to 150 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal	046573

[59 FR 18297, Apr. 18, 1994, as amended at 60 FR 53509, Oct. 16, 1995; 62 FR 9929, Mar. 5, 1997; 63 FR 27845, May 21, 1998; 66 FR 46706, Sept. 7, 2001; 68 FR 13839, Mar. 21, 2003; 68 FR 42590, July 18, 2003; 69 FR 30198, May 27, 2004]

§558.311 Lasalocid.

- (a) Specifications. A minimum of 90 percent of lasalocid activity is derived from lasalocid A.
- (b) Approvals. Type A medicated articles approved for sponsors identified in §510.600(c) of this chapter for use as in paragraph (e) of this section as follows:
- (1) 3.0, 3.3, 3.8, 4.0, 4.3, 4.4, 5.0, 5.1, 5.5, 5.7, 6.0, 6.3, 6.7, 7.2, 7.5, 8.0, 8.3, 10.0, 12.5, 15, 20, and 50 percent activity to No. 046573 for use as in paragraphs (e)(1) (i), (ii), (iii), (iv), and (x) of this section.
- (2) 15 percent activity to No. 066104 as provided by No. 046573 for use as in paragraph (e)(1)(v) of this section.
- (3) 15, 20, 33.1, and 50 percent activity to No. 046573 for use in cattle feeds as in paragraphs (e)(1)(vi), (vii), (ix), (xi), (xii), and (xv) of this section, and for

- use in sheep as in paragraph (e)(1)(viii) of this section.
- (4) 15 percent activity to No. 046573 for use in Type C rabbit feeds as in paragraph (e)(1)(xvi) of this section and for use in ruminant free-choice Type C feeds as in paragraphs (e)(2), (e)(3), and (e)(4) of this section.
- (5) 15 percent activity to 021930 (Type A article provided by 046573) for use in free-choice vitamin-mineral Type C cattle feeds as in paragraph (e)(1)(xi).
- (6) 20 percent activity as a liquid Type A article to No. 046573 for use in cattle feeds as in paragraphs (e)(1)(vi), (e)(1)(vii), (e)(1)(ix), (e)(1)(xi), (e)(1)(xii), and (e)(3) of this section, and for use in sheep feeds as in paragraph (e)(1)(viii) of this section.